Pfizer Turns To Ventana To Expand Companion Dx Options For Xalkori
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer has partnered with Ventana to develop a second companion diagnostic to test for ALK gene mutations to identify patients who could benefit from treatment with Xalkori.